60 Degrees Pharmaceuticals (NASDAQ:SXTP) Upgraded to Hold at Wall Street Zen

60 Degrees Pharmaceuticals (NASDAQ:SXTP) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Several other equities analysts have also weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Friday, March 27th. HC Wainwright increased their target price on shares of 60 Degrees Pharmaceuticals from $6.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $17.60.

60 Degrees Pharmaceuticals Price Performance

Shares of 60 Degrees Pharmaceuticals stock opened at $1.86 on Friday. The stock has a market cap of $1.97 million, a PE ratio of -0.13 and a beta of 3.27. The business has a fifty day simple moving average of $2.92 and a 200-day simple moving average of $3.84. 60 Degrees Pharmaceuticals has a 12 month low of $1.29 and a 12 month high of $17.68.

More 60 Degrees Pharmaceuticals News

Here are the key news stories impacting 60 Degrees Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts sharply (FY2026 from ($5.92) to ($2.21); FY2027 to ($0.54); FY2028 to ($0.44)) while keeping a “Buy” rating and a $24.00 price target — the upgrade in estimates and high price target support a potential re‑rating if clinical or operational progress continues. HC Wainwright Research Note
• Positive Sentiment: Zacks upgraded SXTP to a Zacks Rank #2 (Buy), signaling growing optimism among independent research providers and adding to buying interest from model‑based and retail investors. 60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy
• Neutral Sentiment: 60 Degrees will gain media exposure with interviews airing on the RedChip “Small Stocks, Big Money” show on Bloomberg TV — this can increase awareness and short‑term volume but does not itself change fundamentals. Bloomberg TV Interview Announcement
• Negative Sentiment: Material risks remain: SXTP is loss‑making (consensus negative EPS), has a very small market cap and low average trading volume — these factors make the stock volatile and can limit sustained upside even after bullish research notes.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.